scholarly journals Multicenter Study of Intense Pulsed Light for Patients with Refractory Aqueous-Deficient Dry Eye Accompanied by Mild Meibomian Gland Dysfunction

2020 ◽  
Vol 9 (11) ◽  
pp. 3467
Author(s):  
Reiko Arita ◽  
Shima Fukuoka ◽  
Takanori Mizoguchi ◽  
Naoyuki Morishige
Keyword(s):  
Dry Eye ◽  
Tear Film ◽  
Meibomian Gland ◽  
Intense Pulsed Light ◽  
Meibomian Gland Dysfunction ◽  
Control Group ◽  
Pulsed Light ◽  
Lipid Layer ◽  
Film Stability ◽  
Schirmer’S Test

Aqueous-deficient dry eye (ADDE) and meibomian gland dysfunction (MGD) can be refractory to therapy. Intense pulsed light (IPL) was recently introduced as an effective treatment for MGD. We here evaluated the efficacy of IPL combined with MG expression (MGX) compared with MGX alone (n = 23 and 20, respectively) for patients with refractory ADDE with mild MGD at three sites. Symptom score, visual acuity (VA), noninvasive breakup time (NIBUT) and lipid layer thickness (LLT) of the tear film, lid margin abnormalities, fluorescein BUT (FBUT), fluorescein staining, tear meniscus height (TMH), meibum grade, meiboscore, and Schirmer’s test value were assessed at baseline and 1 and 3 months after treatment. LLT, plugging, vascularity, FBUT and NIBUT were improved only in the IPL-MGX group at three months compared with baseline. All parameters with the exception of VA, meiboscore, TMH, Schirmer’s test value were also improved in the IPL-MGX group compared with the control group at three months, as was VA in patients with central corneal epitheliopathy. Although IPL-MGX does not affect aqueous layer, the induced improvement in quality and quantity of the lipid layer may increase tear film stability and ameliorate symptoms not only for evaporative dry eye but for ADDE.

scholarly journals Use of Intense Pulsed Light to Mitigate Meibomian Gland Dysfunction for Dry Eye Disease

2020 ◽  
Vol 17 (10) ◽  
pp. 1385-1392
Author(s):  
Abhishek Suwal ◽  
Ji-long Hao ◽  
Dan-dan Zhou ◽  
Xiu-fen Liu ◽  
Raja Suwal ◽  
...  
Keyword(s):  
Dry Eye ◽  
Meibomian Gland ◽  
Dry Eye Disease ◽  
Intense Pulsed Light ◽  
Meibomian Gland Dysfunction ◽  
Eye Disease ◽  
Pulsed Light

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

10.3791/57811 ◽  
2019 ◽  
Author(s):  
Luca Vigo ◽  
Giuseppe Giannaccare ◽  
Stefano Sebastiani ◽  
Marco Pellegrini ◽  
Francesco Carones
Keyword(s):  
Dry Eye ◽  
Meibomian Gland ◽  
Intense Pulsed Light ◽  
Meibomian Gland Dysfunction ◽  
Pulsed Light

scholarly journals Intense Pulsed Light (IPL) from Dermatology to Ophthalmology

2021 ◽  
Vol 3 (3) ◽  
pp. 1-3
Author(s):  
Jose Salgado Borges ◽  
C. Vergés ◽  
J. Lima ◽  
March de Ribot F
Keyword(s):  
Dry Eye ◽  
Meibomian Gland ◽  
Dry Eye Disease ◽  
Intense Pulsed Light ◽  
Meibomian Gland Dysfunction ◽  
Eye Disease ◽  
Pulsed Light ◽  
New Treatment

Intense pulsed light (IPL) are medical-esthetical procedures that emit light at a wavelength of 500 – 1200 nm, interacting with epidermal and dermal tissues. IPL is a relatively new treatment of growing popularity thanks to its versatility and efficacy, mainly in dermatology and recently also in ophthalmology. These devices are used to treat dry eye disease, meibomian gland dysfunction, rosacea, and periocular lesions with outstanding results.

scholarly journals Safety and Efficacy of BroadBand Intense Pulsed Light Therapy for Dry Eye Disease with Meibomian Gland Dysfunction

2021 ◽  
Vol Volume 15 ◽  
pp. 3983-3991
Author(s):  
Fahmeeda Murtaza ◽  
Dana Toameh ◽  
Saed Al-Habib ◽  
Raj Maini ◽  
Hannah H Chiu ◽  
...  
Keyword(s):  
Dry Eye ◽  
Light Therapy ◽  
Meibomian Gland ◽  
Dry Eye Disease ◽  
Intense Pulsed Light ◽  
Meibomian Gland Dysfunction ◽  
Eye Disease ◽  
Pulsed Light ◽  
Safety And Efficacy ◽  
Intense Pulsed Light Therapy

A study to assess the efficacy of topical cyclosporine A 0.05% in the management of dry eye with meibomiam gland dysfunction

2022 ◽  
Vol 7 (4) ◽  
pp. 667-671
Author(s):  
Prajwalli Reddy ◽  
Wajeeha Umam
Keyword(s):  
Dry Eye ◽  
Cyclosporine A ◽  
Ocular Surface ◽  
Tear Film ◽  
Meibomian Gland ◽  
Meibomian Gland Dysfunction ◽  
Control Group ◽  
Dry Eyes ◽  
Group A ◽  
Group B

: Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. Meibomian Gland Dysfunction (MGD) is an abnormality of the meibomian gland that blocks the secretion of lipids. Without sufficient lipid production, tears evaporate quickly causing Dry Eye.MGD is associated with multiple pathological mechanisms including inflammation, microbial factors and lipid deficiencies. Topical Cyclosporine A (CsA) 0.05% is a calcineurin inhibitor that reduces inflammation by specifically inhibiting T‑cell activity, which reduces ocular surface inflammation and improves tear film dynamics. This was a prospective observational study done on 100 patients at the Department of Ophthalmology Basaveshwar teaching and general hospital, on patients of dry eyes due to meibomian gland dysfunction. Patients who were diagnosed with dry eyes due to meibomian gland dysfunction were invited to take part in the study. Patients were divided randomly into two groups of 50 patients each. This study, was explained in detail to them. An informed consent was obtained. Patients fulfilling the inclusion criteria were listed.All OSDI scores (symptom intensity, frequency and aggravation) revealed decreasing patterns throughout the observation period in both the groups. In single analysis, the cyclosporine A 0.05% group showed a significant improvement for each score at 3 months (p < 0.01, p = 0.01, p = 0.02, respectively). The mean TBUT after treatment in the group A (cyclosporine A group) increased to 12.36± 3.58(p<0.001) seconds, and in the group B (Control group) the TBUT score increased to 11.01±3.06 seconds. After 3 Months, there was statistically significant improvement in the mean Schirmer’s scores in both the treatment groups, however improvement was significantly greater in Cyclosporine A group. Prior to the treatment in group A (Cyclosporine A) mean Lissamine staining score was 2.73±0.15 and post treatment it reduced to 1.32±0.15 which was statistically significant (P<0.001). In group B (Control group) score before treatment was 2.46±0.15 and after treatment it reduced to 2.39±0.27 (p=0.11), not much difference was seen. : Findings from our study showed that there were significant improvements in the dry eye conditions due to defect in meibomian gland by treatment of topical Cyclosporine A 0.05% and sodium hyaluronate 0.1%.

Sign in / Sign up

Export Citation Format

Share Document